Department of Nutritional Sciences, King's College London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom.
Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
Clin Gastroenterol Hepatol. 2018 Mar;16(3):385-391.e1. doi: 10.1016/j.cgh.2017.09.055. Epub 2017 Oct 7.
BACKGROUND & AIMS: Dietary interventions are effective in management of patients with irritable bowel syndrome (IBS), although responses vary. We investigated whether fecal levels of volatile organic compounds (VOCs) associate with response to dietary interventions in patients with IBS.
Adults who fulfilled the Rome III criteria for IBS were recruited to a 2x2 factorial randomized controlled trial. Patients were randomly assigned to a group counselled to follow a diet low in fructans, galacto-oligosaccharides, lactose, fructose, and polyols (low-FODMAP diet, n = 46) or a group that received placebo dietary advice (sham diet, n = 47) for 4 weeks. Patients from each group were also given either a multi-strain probiotic or placebo supplement. Response was defined as a reduction of 50 points or more on the validated IBS symptom scoring system. Fecal samples were collected from participants at baseline and end of the 4-week study period; VOCs were analyzed by a gas-chromatography sensor device. VOC profiles were determined using a pipeline involving wavelet transformation followed by feature selection based on random forest. A partial least squares classifier was constructed to classify VOC profiles by response and accuracies were determined using 10-fold cross-validation.
Data from 93 patients who completed the study (63 female) were used in the final analysis. More patients responded to the low-FODMAP diet (37/46, 80%) than the sham diet (21/47, 45%) (P < .001), but there was no difference in response between patients given the probiotic (31/49, 63%) vs the placebo (27/44, 61%) (P = .850), with no interaction between the diet and supplement interventions. At baseline, VOC profiles contained 15 features that classified response to the low-FODMAP diet with a mean accuracy of 97% (95% CI, 96%-99%) and 10 features that classified response to probiotic with a mean accuracy of 89% (95% CI, 86%-92%). End of treatment models achieved similar predictive powers and accuracies.
Fecal VOC profiling is a low cost, non-invasive tool that might be used to predict responses of patients with IBS to low-FODMAP diet and probiotics and identify their mechanisms of action. ISRCTN registry no: 02275221.
饮食干预对肠易激综合征(IBS)患者的治疗有效,但患者反应存在差异。我们研究了 IBS 患者粪便中挥发性有机化合物(VOC)的水平是否与饮食干预的反应有关。
符合 Rome III IBS 标准的成年人被招募参加 2x2 析因随机对照试验。患者被随机分为两组,一组接受低果糖、低半乳糖寡糖、乳糖、果糖和多元醇饮食(低 FODMAP 饮食,n = 46),另一组接受安慰剂饮食建议(假饮食,n = 47),持续 4 周。每组患者还给予多菌株益生菌或安慰剂补充剂。以验证的 IBS 症状评分系统减少 50 分或更多为反应标准。在基线和 4 周研究结束时采集参与者的粪便样本;使用气相色谱传感器设备分析 VOC。使用涉及小波变换的管道确定 VOC 谱,并基于随机森林进行特征选择。构建偏最小二乘分类器以根据反应对 VOC 谱进行分类,并使用 10 折交叉验证确定准确性。
93 名完成研究的患者(63 名女性)的数据用于最终分析。接受低 FODMAP 饮食的患者反应更多(37/46,80%),而接受假饮食的患者反应较少(21/47,45%)(P <.001),但给予益生菌(31/49,63%)与安慰剂(27/44,61%)的患者之间无差异(P =.850),饮食和补充干预之间无相互作用。基线时,VOC 谱包含 15 个特征,可将低 FODMAP 饮食的反应分类为 97%(95%CI,96%-99%),10 个特征可将益生菌的反应分类为 89%(95%CI,86%-92%)。治疗结束时的模型达到了类似的预测能力和准确性。
粪便 VOC 分析是一种低成本、非侵入性的工具,可用于预测 IBS 患者对低 FODMAP 饮食和益生菌的反应,并确定其作用机制。ISRCTN 注册编号:02275221。